Intellia Therapeutics (NTLA) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45826J1051

Genome editing, Gene therapies, Cancer treatments

Intellia Therapeutics is a pioneering genome editing company dedicated to developing life-changing, curative treatments. Their innovative approach focuses on using cutting-edge technology to tackle complex diseases.

Their in vivo programs are making significant progress, with NTLA-2001 currently in Phase 1 clinical trials to treat transthyretin amyloidosis, a debilitating condition affecting the heart and nervous system. Additionally, they're working on NTLA-2002 to combat hereditary angioedema, a rare genetic disorder, and NTLA-3001 to address alpha-1 antitrypsin deficiency associated lung disease.

Beyond these programs, Intellia is also exploring treatments for hemophilia A and hemophilia B, as well as researching engineered cell therapies to combat various cancers and autoimmune diseases. Their proprietary programs are pushing the boundaries of medical innovation.

Intellia's toolbox includes the powerful CRISPR/Cas9 system, a precise and efficient genome editing technology. They've formed strategic partnerships with leading biotech companies, including Regeneron Pharmaceuticals, AvenCell Therapeutics, SparingVision, Kyverna Therapeutics, and ONK Therapeutics, to co-develop and commercialize groundbreaking treatments for a range of diseases.

Founded in 2014, Intellia Therapeutics is headquartered in Cambridge, Massachusetts, and is committed to revolutionizing the treatment of genetic diseases. To learn more about their mission and innovative pipeline, visit their website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Intellia Therapeutics (NTLA) - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Intellia Therapeutics (NTLA) - Stock & Dividends

NTLA Stock Overview

Market Cap in USD 2,360m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2016-05-06

NTLA Stock Ratings

Growth 5y 0.92
Fundamental -72.9
Dividend -
Rel. Performance vs Sector -5.73
Analysts -
Fair Price Momentum 21.93 USD
Fair Price DCF -

NTLA Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

NTLA Growth Ratios

Growth 12m -41.68%
Growth Correlation 12m -67%
Growth Correlation 3m -53%
CAGR 5y 12.40%
CAGR/Mean DD 5y 0.28
Sharpe Ratio 12m -0.83
Alpha vs SP500 12m -85.95
Beta vs SP500 5y weekly 1.68
ValueRay RSI 84.74
Volatility GJR Garch 1y 61.77%
Price / SMA 50 4.23%
Price / SMA 200 -11.21%
Current Volume 970.5k
Average Volume 20d 1308.7k

External Links for NTLA Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of NTLA stocks?
As of May 21, 2024, the stock is trading at USD 25.89 with a total of 970,453 shares traded.
Over the past week, the price has changed by +1.85%, over one month by +20.03%, over three months by -4.64% and over the past year by -38.39%.
What are the forecast for NTLA stock price target?
According to ValueRays Forecast Model, NTLA Intellia Therapeutics will be worth about 24.9 in May 2025. The stock is currently trading at 25.89. This means that the stock has a potential downside of -3.86%.
Issuer Forecast Upside
Wallstreet Target Price 70.6 173
Analysts Target Price 83.3 222
ValueRay Target Price 24.9 -3.86